Stem Cell-Derived Blood Products for Therapeutic Use: Technology Improvement (R43/R44)

Funding Agency:
National Institutes of Health
The primary objective of this funding opportunity announcement is to support the development of improved techniques and tools to enhance the production of clinically-relevant, functional stem cell-derived red blood cells or platelets in a more efficient and cost-effective manner. The research supported will develop and enhance technologies that enable the production of functional stem cell-based therapies with potential commercial and clinical viability.
Companion FOAs:
RFA-HL-15-022 supports R01 grants to address the basic or early translational research needs whereas this Small Business Innovation Research (SBIR) Phase I and Phase II (R43/44) FOA along with the companion Small Business Technology Transfer Research (STTR) Phase I (R41) FOA (RFA-HL-15-029 ) supports small business awards to enable further advances in the manufacturing processes.
  • Letter of Intent Due Date(s): 30 days prior to the application due date

  • Application Due Date(s): February 20, 2015 (Phase I or Fast-Track); February 20, 2016 (Phase I; Phase II; or Fast-Track); February 20, 2017 (Phase II only)

RFA-HL-15-030 Expiration Date New Date July 21, 2017 per issuance of NOT-HL-16-464. (Original Expiration Date: February 21, 2017)

Agency Website

Eligibility Requirements

Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.

Funding Type





Engineering and Physical Sciences
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

February 20, 2017